While losing at the EPO, ToolGen escalates battle against Vertex in Europe - JUVE Patent

ToolGen's CRISPR battle against Vertex and Lonza over the genome-editing therapy Casgevy is gathering pace.

Visit Website
While losing at the EPO, ToolGen escalates battle against Vertex in Europe - JUVE Patent - JUVE Patent | Aetos.AI